Ono Pharmaceutical - More Bad News As Tecentriq's OAK Trial Goes Well
Roche's US subsidiary, Genentech announced that the OAK trial for Tecentriq met its primary endpoint (a statistically significant and clinically...
347 Views
Opdivo Fails NSCLC Test
Ono Pharmaceutical's US partner, Bristol Myers Squibb reported that Opdivo didn’t meet its primary goal of lengthening progression-free survival in...
331 Views
Ono & Opdivo: Is the Backlash Orchestrated?
The announcement by the Japan Society of Medical Oncology (JSMO) urging patients to take caution over usage of immune checkpoint inhibitors, such...
418 Views